Changeflow GovPing Healthcare & Life Sciences Hispidin Derivative Synthesis Method and Use
Routine Notice Added Draft

Hispidin Derivative Synthesis Method and Use

Email

Summary

The USPTO has published a patent application (US20260085054A1) detailing a new method for synthesizing Hispidin derivatives and their use in preparing lipid-lowering drugs. The application describes a process using readily available starting materials with potential for large-scale industrial application.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application from the USPTO, not a regulatory rule or enforcement action. It discloses a novel method for synthesizing Hispidin derivatives, specifically those with a styrylpyrone backbone, using 4-hydroxy-6-methyl-2-pyrone and 3,4-dihydroxybenzaldehyde. The application highlights the simplicity, operational ease, feasibility for large-scale industrial application, and broad market prospects of the preparation method. It also details the use of these derivatives in the preparation of lipid-lowering drugs, indicating a good therapeutic effect and potential for significant social benefits.

While this is a patent application and not a direct regulatory mandate, companies involved in pharmaceutical research and development, particularly in the area of lipid-lowering drugs or organic synthesis, should be aware of this disclosure. The inventors claim novelty in the synthesis method and the derivative itself, which could impact future patentability and market exclusivity for similar compounds. Compliance officers in the pharmaceutical sector should monitor the progression of this patent application and similar disclosures to understand potential intellectual property landscapes and competitive developments in drug synthesis and therapeutic applications.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

DERIVATIVE OF HISPIDIN FROM SANGHUANGPORUS SANGHUANG, AND PREPARATION METHOD AND USE THEREOF

Application US20260085054A1 Kind: A1 Mar 26, 2026

Inventors

Chengfu Yuan, Zhiwen Zhou, Yuting Liu, Hongqi Zhang

Abstract

The present disclosure relates to the technical field of drug synthesis, and particularly relates to a Hispidin derivative, and a preparation method and use thereof. The Hispidin derivative has a structure of formula (I): The present disclosure employs 4-hydroxy-6-methyl-2-pyrone and 3,4-dihydroxybenzaldehyde as starting raw materials to synthesize a series of compounds with styrylpyrone as a backbone. The preparation method provided by the present disclosure has simple steps, is easy to operate, has good feasibility, has the potential for large-scale industrial application, and has a broad market prospect. The present disclosure further provides use of the preparation method described above and the resulting Hispidin derivative in preparation of a lipid-lowering drug. The aryl compound provided by the present disclosure has a good lipid-lowering therapeutic effect and can be used for preparing a lipid-lowering drug, thus having good social benefits.

CPC Classifications

C07D 309/36 A61K 31/366 A61P 3/06 C07D 405/06

Filing Date

2025-11-26

Application No.

19401409

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260085054A1

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Synthesis Drug Development
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Drug Development Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!